Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 14.19% and Operating profit at -10.35% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 9.15% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 14.19% and Operating profit at -10.35% over the last 5 years
3
The company has declared negative results for the last 6 consecutive quarters
4
With ROE of 2.57%, it has a very expensive valuation with a 12.64 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 31,271 Million (Large Cap)
492.00
NA
0.13%
0.65
2.57%
12.64
Revenue and Profits:
Net Sales:
286 Million
(Quarterly Results - Jun 2025)
Net Profit:
6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-42.54%
0%
-42.54%
6 Months
2.76%
0%
2.76%
1 Year
58.03%
0%
58.03%
2 Years
45.3%
0%
45.3%
3 Years
127.06%
0%
127.06%
4 Years
37.14%
0%
37.14%
5 Years
5.59%
0%
5.59%
BrightGene Bio-Medical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.19%
EBIT Growth (5y)
-10.35%
EBIT to Interest (avg)
25.45
Debt to EBITDA (avg)
3.56
Net Debt to Equity (avg)
0.57
Sales to Capital Employed (avg)
0.26
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
21.42%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.70%
ROE (avg)
9.15%
Valuation key factors
Factor
Value
P/E Ratio
492
Industry P/E
Price to Book Value
12.64
EV to EBIT
390.25
EV to EBITDA
141.48
EV to Capital Employed
8.06
EV to Sales
28.55
PEG Ratio
NA
Dividend Yield
0.13%
ROCE (Latest)
2.07%
ROE (Latest)
2.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
285.70
246.30
16.00%
Operating Profit (PBDIT) excl Other Income
59.30
32.30
83.59%
Interest
14.10
15.00
-6.00%
Exceptional Items
-0.10
1.70
-105.88%
Consolidate Net Profit
6.30
-4.70
234.04%
Operating Profit Margin (Excl OI)
62.00%
-37.90%
9.99%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 16.00% vs -18.55% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 234.04% vs 14.55% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,274.10
1,173.80
8.54%
Operating Profit (PBDIT) excl Other Income
313.50
288.00
8.85%
Interest
53.80
44.70
20.36%
Exceptional Items
-10.10
-0.50
-1,920.00%
Consolidate Net Profit
141.30
173.40
-18.51%
Operating Profit Margin (Excl OI)
151.40%
169.90%
-1.85%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 8.54% vs 15.98% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -18.51% vs -17.98% in Dec 2023
About BrightGene Bio-Medical Technology Co., Ltd. 
BrightGene Bio-Medical Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






